See the latest news and media coverage for Repertoire. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing immune medicines
repertoire.comLast updated
In short: Repertoire entered a $1.9 billion autoimmune partnership with Eli Lilly and advanced its lead cancer therapy into Phase 1/2 clinical trials.
The designation targets HLA-A*02:01-positive patients with unresectable or metastatic triple-negative breast cancer after standard therapies. RPTR-1-201, a TCR bispecific, is in Phase 1/2 trials.
The accomplishment highlights the agility and perseverance of their talented R&D group advancing cancer therapy urgently.
The Phase 1/2 trial evaluates safety, tolerability, and antitumor activity of the TCR bispecific therapy for advanced solid tumors, as monotherapy and with anti-PD-1.
The partnership uses Repertoire's DECODE platform to develop tolerizing therapies for autoimmune diseases. Lilly leads clinical development and commercialization.
Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that the U.S. Food and Drug...
Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that the first participant has been...
The deal underscores a broader shift in autoimmune drug development toward therapies that aim to reprogram disease-driving immune responses at their source.
Repertoire Immune Medicines has collaborated with Eli Lilly for the development of tolerising therapies to treat several autoimmune diseases.
Track Repertoire and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Repertoire and other trending companies.